Skip to main content
SpringerLink
Log in

A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined.

Methods

Five patients are briefly presented who were found to have extensive intra-abdominal carcinomatosis from ovarian/peritoneal cancers and were initially treated with a carboplatin/paclitaxel-based neoadjuvant chemotherapy program. Following major objective and subjective responses each patient underwent a surgical re-assessment and subsequently received single-agent intraperitoneal platinum (cisplatin or carboplatin).

Results and conclusion

In the absence of definitive data from randomized phase-3 trials defining optimal management in this setting, a rational argument can be provided supporting the use of this multi-modality management strategy (neoadjuvant chemotherapy followed by surgery and regional chemotherapy) in carefully selected patients presenting with extensive ovarian or primary peritoneal cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ansquer V, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud J-D, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma. A French multicenter study. Cancer 91:2329–2334

    Article  CAS  PubMed  Google Scholar 

  • Barakat RR, Almadrones L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, Curtin JP, Spriggs D (1998) A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II–IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol 69:17–22

    Article  CAS  PubMed  Google Scholar 

  • Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20:694–698

    Article  PubMed  Google Scholar 

  • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259

    Article  PubMed  Google Scholar 

  • Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr (1983) Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep 67:235–238

    CAS  PubMed  Google Scholar 

  • Chan YM, Ng TY, Ngan HYS, Wong LC (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88:9–16

    Article  CAS  PubMed  Google Scholar 

  • Covens AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78:269–274

    Article  CAS  PubMed  Google Scholar 

  • DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, Sikic BI (1986) Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18:235–238

    CAS  PubMed  Google Scholar 

  • Eisenkop SM, Friedman RL, Wang H-J (1998) Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69:103–108

    Article  CAS  PubMed  Google Scholar 

  • Elferink F, van der Vijgh WJF, Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:57–60

    CAS  PubMed  Google Scholar 

  • Girling JC, Soutter WP (1996) Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate. Int J Gynecol Cancer 6:81–84

    Article  Google Scholar 

  • Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166

    Article  CAS  PubMed  Google Scholar 

  • Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851

    CAS  PubMed  Google Scholar 

  • Kayikciog Lu F, Kose MF, Boran N, Caliskan E, Tulunay G (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11:466–470

    Article  PubMed  Google Scholar 

  • Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, Hundelshausen B von, Pachyn D, Ulm K, Graeff H (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer 2585–2591

  • Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS (2002) The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 85:351–355

    Article  PubMed  Google Scholar 

  • Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49:3380–3384

    CAS  PubMed  Google Scholar 

  • Los G, Mutsaers PHA, Lenglet WJM, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389–394

    CAS  PubMed  Google Scholar 

  • Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277–283

    Article  CAS  PubMed  Google Scholar 

  • Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801–1805

    CAS  PubMed  Google Scholar 

  • Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W (1992) Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10:1479–1484

    CAS  PubMed  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6

    Article  CAS  PubMed  Google Scholar 

  • Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165:875–878

    CAS  Google Scholar 

  • Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18:106–115

    CAS  PubMed  Google Scholar 

  • Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD (1983) Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085–1092

    CAS  PubMed  Google Scholar 

  • Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH (2002) A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 21:201a

    Google Scholar 

  • Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72:93–99

    Article  CAS  PubMed  Google Scholar 

  • Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D (1996) Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 6:356–361

    Article  Google Scholar 

  • van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S, for the Gynecological Cooperative Group of the European Organization for Research and Treatment of Cancer (1995) N Engl J Med 332:629–634

    Article  PubMed  Google Scholar 

  • Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71:431–436

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Maurie Markman & Jerome Belinson

  2. Department of Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Mail Box #121, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerome Belinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurie Markman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M., Belinson, J. A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J Cancer Res Clin Oncol 131, 26–30 (2005). https://doi.org/10.1007/s00432-004-0624-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-004-0624-1

Keywords

Search

Navigation